Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.36M Sell
3,755
-47
-1% -$16.1K 1.1% 31
2026
Q1
$1.34M Buy
3,802
+85
+2% +$30.3K 1.15% 29
2025
Q4
$1.22M Buy
3,717
+6
+0.2% +$1.9K 1.08% 31
2025
Q3
$1.05M Sell
3,711
-88
-2% -$25.5K 0.95% 35
2025
Q2
$1.06M Buy
3,799
+45
+1% +$12.7K 0.94% 36
2025
Q1
$1.17M Sell
3,754
-290
-7% -$85.6K 1.11% 23
2024
Q4
$1.05M Sell
4,044
-243
-6% -$72.1K 0.97% 36
2024
Q3
$1.38M Sell
4,287
-24
-0.6% -$7.85K 1.21% 32
2024
Q2
$1.35M Buy
4,311
+2,554
+145% +$750K 1.25% 26
2024
Q1
$500K Sell
1,757
-2,301
-57% -$673K 0.46% 52
2023
Q4
$1.17M Buy
4,058
+19
+0.5% +$5.18K 1.12% 32
2023
Q3
$1.09M Buy
4,039
+89
+2% +$22.2K 1.16% 29
2023
Q2
$877K Sell
3,950
-179
-4% -$41.5K 0.93% 43
2023
Q1
$998K Buy
4,129
+2,179
+112% +$535K 1.08% 36
2022
Q4
$512K Sell
1,950
-688
-26% -$184K 0.59% 47
2022
Q3
$595K Sell
2,638
-263
-9% -$63.8K 0.72% 42
2022
Q2
$706K Buy
2,901
+49
+2% +$12K 0.78% 43
2022
Q1
$690K Sell
2,852
-1,193
-29% -$274K 0.69% 43
2021
Q4
$910K Buy
+4,045
New +$854K 0.85% 41

Other funds holding AMGN

DB Fitzpatrick & Co's AMGN Position: Q2 2026 in Review

DB Fitzpatrick & Co reduced its Amgen (AMGN) stake by 1.2% in Q2 2026, selling an estimated $16.1K and leaving 3,755 shares worth $1.36M. The position accounts for 1.1% of the portfolio, ranked #31.

DB Fitzpatrick & Co first reported a position in AMGN in Q4 2021 and has held it in 19 quarters since. The position peaked at $1.38M in Q3 2024. 1,543 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • DB Fitzpatrick & Co held 3,755 shares of Amgen worth $1.36M as of Q2 2026.
  • DB Fitzpatrick & Co sold 47 Amgen shares in Q2 2026, an estimated $16.1K.
  • Amgen made up 1.1% of DB Fitzpatrick & Co's portfolio in Q2 2026, its #31 holding.
  • DB Fitzpatrick & Co first reported a position in Amgen in Q4 2021 and has held it in 19 quarters since.
  • DB Fitzpatrick & Co's Amgen position peaked at $1.38M in Q3 2024.
  • 1,543 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on DB Fitzpatrick & Co's 13F filing for Q2 2026, filed 15 Jul 2026.